Development Of Skin Rash Within The 1st Week Is A Potential Surrogate Marker Of Therapeutic Effect In Afatinib Monotherapy In Patients With Egfr-Mt Non-Small-Cell Lung Cancer (Nsclc): Okayama Lung Cancer Study Group Experience.

e19051 Background: EGFR-TKI, gefitinib or erlotinib, is a key drug in pts with EGFR-mt NSCLC. Its efficacy would be predicted by development of skin rash [J Clin Oncol 2006].). However, although afatinib, 2nd generation EGFR-TKI, has proved to be effective [Lancet Oncol 2015], it has not been fully evaluated if the occurrence of any toxicity is a potential surrogate for its efficacy. Now, we investigated a potential association between development of toxicity and efficacy of afatinib. Methods: We retrospectively studied 49 pts with EGFR-mt NSCLC who received afatinib therapy between 2014 and 2015. Relationship with several toxicities and tumor response was examined by chi-square test. To avoid the potential bias of early treatment failure, we excluded pts who failed to continue afatinib for more than 1week. Results: Pt demographics were as follows: men, 17; median age, 69 yrs; PS 0-1, 40; stage IV, 41; Ad, 49; prior TKI use, 26; exon19, 28. The ≥ G2 adverse events (AEs) were hepatitis in 2 pts (4%), skin ...